AQUIPTA™ is indicated for prophylaxis
of migraine in adults who have at least
4 migraine days per month.1
The only oral, once-daily CGRP receptor antagonist indicated for prevention of episodic and chronic migraine*1,2
AQUIPTA™ has demonstrated inhibitory effects at the CGRP receptor and the amylin-1 receptor.1
CGRP is a neuropeptide that has been associated with, and plays an important role in, migraine pathophysiology.1,3 During a migraine attack, serum levels of the neuropeptide increase.3,4 CGRP attaches to its receptors, inducing pain, inflammation and vasodilation.5
The precise mechanism of action of AQUIPTA™ in the prevention of migraine has yet to be established.1
CGRP ELEVATED
DURING MIGRAINE3,4
AQUIPTA™ INHIBITS CGRP
AT ITS RECEPTORS1
Adapted from Edvinsson L, et al.6 For illustrative purposes only.
CGRP, calcitonin gene-related peptide; IE, Ireland.
*In adults who have at least 4 migraine days per month.1
References:
- AQUIPTA™ (atogepant) IE Summary of Product Characteristics. August 2023.
- Morena-Ajona D, et al. J Clin Med. 2022;11(6):1656.
- Rivera-Mancilla E, et al. Expert Opin Drug Saf. 2020;19:1237–1250.
- Ferrari MD, et al. Nat Rev Dis Primers. 2022;8(1):2.
- Goadsby PJ, et al. Physiol Rev. 2017;97(2):553–622.
- Edvinsson L, et al. Nat Rev Neurol. 2018;14(6):338–350.
ALL-AQP-230003 March 2024